Terms: = Prostate cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Clinical Outcome
17 results:
1. Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced prostate cancer.
Neeb A; Figueiredo I; Gurel B; Nava Rodrigues D; Rekowski J; Riisnaes R; Ferreira A; Miranda S; Crespo M; Westaby D; de Los Dolores Fenor de La Maza M; Guo C; Carmichael J; Grochot R; Tunariu N; Cato ACB; Plymate SR; de Bono JS; Sharp A
Lab Invest; 2023 Nov; 103(11):100245. PubMed ID: 37652207
[TBL] [Abstract] [Full Text] [Related]
2. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA.
Kang M; Ren M; Li Y; Fu Y; Deng M; Li C
J Exp Clin Cancer Res; 2018 Jul; 37(1):171. PubMed ID: 30049286
[TBL] [Abstract] [Full Text] [Related]
3. bcl2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
Oing C; Tennstedt P; Simon R; Volquardsen J; Borgmann K; Bokemeyer C; Petersen C; Dikomey E; Rothkamm K; Mansour WY
Cancer Lett; 2018 Jun; 423():60-70. PubMed ID: 29526801
[TBL] [Abstract] [Full Text] [Related]
4. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for prostate cancer.
Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R
J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214
[TBL] [Abstract] [Full Text] [Related]
5. MR-based prognostic nomogram for prostate cancer after radical prostatectomy.
Zhang YD; Wu CJ; Bao ML; Li H; Wang XN; Liu XS; Shi HB
J Magn Reson Imaging; 2017 Feb; 45(2):586-596. PubMed ID: 27654116
[TBL] [Abstract] [Full Text] [Related]
6. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract] [Full Text] [Related]
7. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study.
Abdulkader I; Sánchez L; Cameselle-Teijeiro J; Gude F; Chávez JE; López-López R; Forteza J; Fraga M
Oncol Rep; 2005 Dec; 14(6):1527-31. PubMed ID: 16273250
[TBL] [Abstract] [Full Text] [Related]
8. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract] [Full Text] [Related]
9. Expression of bcl-2 family member Bid in normal and malignant tissues.
Krajewska M; Zapata JM; Meinhold-Heerlein I; Hedayat H; Monks A; Bettendorf H; Shabaik A; Bubendorf L; Kallioniemi OP; Kim H; Reifenberger G; Reed JC; Krajewski S
Neoplasia; 2002; 4(2):129-40. PubMed ID: 11896568
[TBL] [Abstract] [Full Text] [Related]
10. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.
Szostak MJ; Kaur P; Amin P; Jacobs SC; Kyprianou N
J Urol; 2001 Jun; 165(6 Pt 1):2126-30. PubMed ID: 11371940
[TBL] [Abstract] [Full Text] [Related]
11. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
Borre M; Stausbol-Gron B; Overgaard J
J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
[TBL] [Abstract] [Full Text] [Related]
12. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract] [Full Text] [Related]
13. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
[TBL] [Abstract] [Full Text] [Related]
14. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
[TBL] [Abstract] [Full Text] [Related]
15. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract] [Full Text] [Related]
16. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer.
Stattin P; Westin P; Damber JE; Bergh A
Br J Cancer; 1998 Feb; 77(4):670-5. PubMed ID: 9484828
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic significance of bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract] [Full Text] [Related]
